BIELLO, FEDERICA
 Distribuzione geografica
Continente #
EU - Europa 2.818
AS - Asia 452
NA - Nord America 304
SA - Sud America 40
AF - Africa 9
Totale 3.623
Nazione #
IT - Italia 2.745
US - Stati Uniti d'America 292
SG - Singapore 155
CN - Cina 107
VN - Vietnam 84
BD - Bangladesh 52
FR - Francia 29
BR - Brasile 23
HK - Hong Kong 22
DE - Germania 9
AR - Argentina 8
CA - Canada 6
FI - Finlandia 6
GB - Regno Unito 6
JP - Giappone 5
PH - Filippine 5
TR - Turchia 5
EC - Ecuador 4
ID - Indonesia 4
NL - Olanda 4
IN - India 3
JM - Giamaica 3
MY - Malesia 3
PL - Polonia 3
BE - Belgio 2
CH - Svizzera 2
DZ - Algeria 2
ET - Etiopia 2
IE - Irlanda 2
MX - Messico 2
PY - Paraguay 2
SE - Svezia 2
UA - Ucraina 2
ZA - Sudafrica 2
AL - Albania 1
AM - Armenia 1
AT - Austria 1
CO - Colombia 1
HN - Honduras 1
IQ - Iraq 1
KE - Kenya 1
KG - Kirghizistan 1
LB - Libano 1
LV - Lettonia 1
MU - Mauritius 1
NP - Nepal 1
PE - Perù 1
PK - Pakistan 1
RS - Serbia 1
RU - Federazione Russa 1
SI - Slovenia 1
TN - Tunisia 1
UY - Uruguay 1
UZ - Uzbekistan 1
Totale 3.623
Città #
Genoa 1.056
Genova 1.000
Rapallo 386
Vado Ligure 247
San Jose 79
Singapore 66
Ashburn 52
Lauterbourg 25
Hanoi 24
Ho Chi Minh City 23
Hong Kong 22
Beijing 21
New York 19
Council Bluffs 18
St Louis 10
Frankfurt am Main 8
Bordighera 6
Buffalo 6
Los Angeles 6
São Paulo 6
Helsinki 5
Milan 4
Rome 4
Santa Clara 4
Tokyo 4
Atlanta 3
Biên Hòa 3
Houston 3
Naples 3
Addis Ababa 2
Amsterdam 2
Ancona 2
Brussels 2
Bình Dương 2
Chicago 2
City of London 2
Cleveland 2
Da Nang 2
Davao City 2
Dhaka 2
Dublin 2
Guayaquil 2
Haiphong 2
Hefei 2
Istanbul 2
Johannesburg 2
Kingston 2
Kyiv 2
Orem 2
Paris 2
Petaling Jaya 2
Resistencia 2
Shenzhen 2
Stockholm 2
Thái Nguyên 2
Tianjin 2
Toronto 2
Vinh 2
Warsaw 2
Zurich 2
Alexandria 1
Anna 1
Arapiraca 1
Arlington 1
Artena 1
Asunción 1
Avezzano 1
Bacoor 1
Baghdad 1
Bari 1
Barletta 1
Batna City 1
Belgrade 1
Bengaluru 1
Birmingham 1
Bishkek 1
Boardman 1
Braço do Norte 1
Brooklyn 1
Bình Phước 1
Cagliari 1
Camaçari 1
Camporotondo Etneo 1
Cardito 1
Cartagena 1
Catania 1
Chino 1
Chula Vista 1
Colonia San Eduardo 1
Cuiabá 1
Dallas 1
Dasmariñas 1
Denver 1
Dolianova 1
Egg Harbor Township 1
El Paso 1
Gaziantep 1
General Pico 1
Girifalco 1
Guangzhou 1
Totale 3.215
Nome #
The role of CEA, CYFRA21-1 and NSE in monitoring tumor response to Nivolumab in advanced non-small cell lung cancer (NSCLC) patients 191
Fibroblast Growth Factor Receptor (FGFR): A New Target for Non-small Cell Lung Cancer Therapy 176
Baseline serum levels of osteopontin predict clinical response to treatment with nivolumab in patients with non-small cell lung cancer 176
Circulating tumor DNA reflects tumor metabolism rather than tumor burden in chemotherapy-naive patients with advanced non–small cell lung cancer:18F-FDG PET/CT study 174
Uncommon EGFR Exon 19 Mutations Confer Gefitinib Resistance in Advanced Lung Adenocarcinoma 167
Serial Troponin for Early Detection of Nivolumab Cardiotoxicity in Advanced Non-Small Cell Lung Cancer Patients 162
Serum PCSK9 levels at the second nivolumab cycle predict overall survival in elderly patients with NSCLC: a pilot study 159
Clinical applications of circulating tumor cells in lung cancer patients by cellsearch system 152
Comparison between 18F-FDG-PET- and CT-based criteria in non-small cell lung cancer (NSCLC) patients treated with Nivolumab 148
Nivolumab treatment in advanced lung cancer patient with chronic active hepatitis C and systemic lupus erythematosus. 132
Afatinib for the treatment of non-small cell lung cancer 131
New systemic strategies for overcoming resistance to targeted therapies in non-small cell lung cancer 131
Releasing the brake: safety profile of immune check-point inhibitors in non-small cell lung cancer 131
Current state of the art on the diagnosis and the role of target therapy for treatment of ROS1-rearranged non-small cell lung cancer: a narrative review 124
Resistin is associated with overall survival in non-small cell lung cancer patients during nivolumab treatment 124
Circulating cell-free DNA and circulating tumor cells as prognostic and predictive biomarkers in advanced non-small cell lung cancer patients treated with first-line chemotherapy 122
CIMAvax-EGF, a therapeutic non-small cell lung cancer vaccine 117
The role of the immune metabolic prognostic index in patients with non-small cell lung cancer (Nsclc) in radiological progression during treatment with nivolumab 115
Investigational drugs targeting fibroblast growth factor receptor in the treatment of non-small cell lung cancer 112
Afatinib and Erlotinib in the treatment of squamous-cell lung cancer 111
Serum levels of VCAM-1 are associated with survival in patients treated with nivolumab for NSCLC 110
Vinflunine for the treatment of non-small cell lung cancer 103
Extracellular vesicles miR-574-5p and miR-181a-5p as prognostic markers in NSCLC patients treated with nivolumab 100
Prognostic role of the VeriStrat test in first line patients with non-small cell lung cancer treated with platinum-based chemotherapy 96
Novel approaches for the treatment of unresectable malignant pleural mesothelioma: A focus on immunotherapy and target therapy (Review) 93
The evolving role of pemetrexed disodium for the treatment of non-small cell lung cancer 90
Serum proteomic test in advanced non-squamous non-small cell lung cancer treated in first line with standard chemotherapy 86
Current state of the art and future perspectives with immunotherapy in the management of small cell lung cancer 77
Prognostic relevance of circulating tumor cells and circulating cell-free DNA association in metastatic non-small cell lung cancer treated with nivolumab 61
Determinants of 5-year survival in patients with advanced NSCLC with PD-L1≥50% treated with first-line pembrolizumab outside of clinical trials: results from the Pembro-real 5Y global registry 23
Improved overall survival in patients developing endocrine toxicity during treatment with nivolumab for advanced non-small cell lung cancer in a prospective study 19
Long-term outcomes from pembrolizumab monotherapy in patients with advanced NSCLC, PD-L1 expression ≥ 50 %, and poor performance status: Transformer-based AI to characterize prognostic complexity 16
Transformer-based AI approach to unravel long-term, time-dependent prognostic complexity in patients with advanced NSCLC and PD-L1 ≥50%: insights from the pembrolizumab 5-year global registry 7
Totale 3.736
Categoria #
all - tutte 15.132
article - articoli 15.132
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 30.264


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202119 0 0 0 0 0 0 0 0 0 0 0 19
2021/2022296 16 8 10 18 14 23 6 63 36 34 15 53
2022/2023431 27 36 8 39 75 68 0 43 65 5 61 4
2023/2024278 7 24 11 36 20 66 14 25 11 26 4 34
2024/2025684 35 41 17 56 77 69 59 156 24 38 62 50
2025/20261.246 172 20 72 93 170 64 179 50 116 138 122 50
Totale 3.736